newsfilter
← Latest News
Business Wire·

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug